Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-711 first-in-human study in advanced squamous tumors
jRCT2051250169Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of ABBV-711 and budigalimab in squamous cell carcinoma (SCC) (6 arms), sponsored by AbbVie Inc. Primary endpoints: Number of participants with adverse events and Best overall response. Started Dec 2025; status: recruiting.
02
Drugs
ABBV-711budigalimab
03
Conditions
squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on jRCT2051250169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250169.